Medidata Institute Redefines Technology’s Role in Advancing Science and Healthcare

• Institute collaborates with leading influencers in life sciences to
  solve industry challenges and provide fresh perspectives
• Initial partnerships with Castleman Disease Collaborative Network
  and Friends of Cancer Research deliver insights that improve treatment
  options and reduce the need for control arm patients

NEW YORK–(BUSINESS WIRE)–#MDSO—Medidata
(NASDAQ:MDSO) announced today that the Medidata Institute is working
with industry partners to deliver insights that redefine how technology,
data and AI can improve lives and inspire the next generation of medical
treatments.

Medidata’s decades of technical and industry experience uniquely
position the company to work with and unite leaders across the life
sciences via the Medidata Institute – including researchers, regulatory
bodies, patient advocacy groups and other organizations.

“The Medidata Institute was established in support of our company’s
mission of powering smarter treatments and healthier people,” said Glen
de Vries, co-founder and president, Medidata. “This forum challenges the
industry to think in new ways about how technology can fundamentally
improve the way we conduct research and deliver treatments to patients
in need.”

To date, Medidata has partnered with Friends of Cancer Research (Friends)
and The Castleman Disease Collaborative Network (CDCN) — two
organizations focused on bringing better treatments to patients through
collaboration.

Medidata is part of a working group led by Friends comprised of
representatives from the FDA, pharmaceutical companies, academia and
patient advocacy. The group seeks to address the challenge of randomized
control trials and explores the power of external controls, such as
synthetic control arms (SCA).

By leveraging advanced analytics and patient-level data from multiple
historical clinical trials, Medidata and Friends demonstrated in
a non-small cell lung cancer case study that SCAs can mimic the results
of a traditional randomized control. Specifically, the overall survival
(OS) of the target randomized control was replicated by the SCA. These
findings hold promise in identifying ways to reduce the number of
patients needed for a randomized control arm. More information can be
found here.

“The vast amount of data available in the life sciences today offers an
opportunity to transform the clinical trial process,” said Mark Stewart,
vice president, science policy, Friends of Cancer Research. “Partnering
with the Medidata Institute to make these data actionable is a
game-changing effort that will enhance the clinical trial experience for
patients and propel next gen therapies.”

Medidata has also partnered with CDCN to advance personalized medicine
for patients with this life-threatening, rare disorder. Using a machine
learning-based solution, researchers discovered new patient subgroups
within a population of Castleman Disease patients and uncovered novel
insights into treatment response and potential new drug targets for
these patients.

To learn more about the Medidata Institute and the insights being
uncovered, visit here.

About Friends of Cancer Research
Friends of Cancer Research (Friends)
drives collaboration among partners from every healthcare sector to
power advances in science, policy, and regulation that speed lifesaving
treatments to patients. For more information, please visit www.focr.org.

About the Medidata Institute
Building on more than 20 years
experience in technology, data and analytics, Medidata launched the
Medidata Institute to provide unique insights, inspire the next
generation of treatments, and improve patient lives. The Medidata
Institute works in partnership with life science companies, researchers,
regulatory agencies, patient advocates and international organizations
to solve challenges in treatment research, development, and delivery.

About Medidata
Medidata is leading the digital
transformation of life science, with the world’s most used platform for
clinical development, commercial, and real-world data. Powered by
artificial intelligence and delivered by top ranked industry experts,
Medidata helps pharmaceutical, biotech, medical device companies, and
academic researchers accelerate value, minimize risk and optimize
outcomes. Medidata and its companies, Acorn AI and SHYFT, serve more
than 1,200 customers and partners worldwide and empower more than
150,000 certified users every day to create hope for millions of
patients. Discover the future of life science: www.medidata.com

Contacts

Medidata Solutions
Investors:
Betsy Frank, +1
917-522-4620
[email protected]

Media:
Erik Snider, +1 646-362-2997
[email protected]